Mutant p53-ENTPD5 control of the calnexin/calreticulin cycle: a druggable target for inhibiting integrin-α5-driven metastasis

BACKGROUND: TP53, encoding the tumor suppressor p53, is frequently mutated in various cancers, producing mutant p53 proteins (mutp53) which can exhibit neomorphic, gain-of-function properties. The latter transform p53 into an oncoprotein that promotes metastatic tumor progression via downstream effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Pavlakis, Evangelos, Neumann, Michelle, Merle, Nastasja, Wieboldt, Ronja, Wanzel, Michael, Ponath, Viviane, Pogge von Strandmann, Elke, Elmshäuser, Sabrina, Stiewe, Thorsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413714/
https://www.ncbi.nlm.nih.gov/pubmed/37563605
http://dx.doi.org/10.1186/s13046-023-02785-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413714/
https://www.ncbi.nlm.nih.gov/pubmed/37563605
http://dx.doi.org/10.1186/s13046-023-02785-z

Ejemplares similares